Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Atreca stock

Learn how to easily invest in Atreca stock.

Atreca Inc is a biotechnology business based in the US. Atreca shares (BCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Atreca employs 134 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Atreca

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BCEL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Atreca stock price (NASDAQ: BCEL)

Use our graph to track the performance of BCEL stocks over time.

Atreca shares at a glance

Information last updated 2022-07-03.
Latest market close$2.23
52-week range$1.51 - $9.77
50-day moving average $1.87
200-day moving average $3.26
Wall St. target price$14.89
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.91

Buy Atreca shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Atreca stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Atreca price performance over time

Historical closes compared with the close of $2.23 from 2022-07-05

1 week (2022-06-29) 21.86%
1 month (2022-06-02) 42.95%
3 months (2022-04-05) -28.06%
6 months (2022-01-02) N/A
1 year (2021-07-06) -74.69%
2 years (2020-07-06) -90.38%
3 years (2019-07-05) 16.22
5 years (2017-07-02) N/A

Atreca financials

Gross profit TTM $0
Return on assets TTM -28.86%
Return on equity TTM -60.37%
Profit margin 0%
Book value $3.57
Market capitalisation $69.1 million

TTM: trailing 12 months

Atreca share dividends

We're not expecting Atreca to pay a dividend over the next 12 months.

Have Atreca's shares ever split?

Atreca's shares were split on a 1:6 basis on 6 June 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Atreca shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Atreca shares which in turn could have impacted Atreca's share price.

Atreca share price volatility

Over the last 12 months, Atreca's shares have ranged in value from as little as $1.51 up to $9.77. A popular way to gauge a stock's volatility is its "beta".

BCEL.US volatility(beta: 0.78)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atreca's is 0.7785. This would suggest that Atreca's shares are less volatile than average (for this exchange).

Atreca overview

Atreca, Inc. , a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria.

Frequently asked questions

What percentage of Atreca is owned by insiders or institutions?
Currently 3.219% of Atreca shares are held by insiders and 61.479% by institutions.
How many people work for Atreca?
Latest data suggests 134 work at Atreca.
When does the fiscal year end for Atreca?
Atreca's fiscal year ends in December.
Where is Atreca based?
Atreca's address is: 835 Industrial Road, South San Francisco, CA, United States, 94070
What is Atreca's ISIN number?
Atreca's international securities identification number is: US04965G1094
What is Atreca's CUSIP number?
Atreca's Committee on Uniform Securities Identification Procedures number is: 04965G109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site